Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03122717 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03122717 · ClinicalTrials.gov record · last posted 2026-04-29

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Name: Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — clinical trial record (NCT03122717)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1/2

SponsorDana-Farber Cancer Institute

Started2017-05-09

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The interventions involved in this study are: * Osimertinib (Tagrisso) * Gefitinib (Iressa)

Amendment record 24 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 24 times since 2017-04-18; most recent amendment 2026-04-24. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2020-10-30

Status change Recruiting→Active, Not Recruitingv9

2017-08-10

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT03122717
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: AstraZeneca
Conditions	Non-Small Cell Lung Cancer
Enrollment	48 participants
Start Date	2017-05-09
Primary Completion	2026-10 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-04-29